To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 Months) Previously Vaccinated in the Primary Study NCT00307554 With Either Pneumococcal Vaccine or Prevenar™
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Infections, Streptococcal
- Sponsor
- GlaxoSmithKline
- Enrollment
- 1200
- Locations
- 1
- Primary Endpoint
- Number of Subjects With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) Post Booster Between the Synflorix-Synflorix and Prevenar-Prevenar Groups
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either pneumococcal vaccine or Prevenar™ in study 105553. Antibody persistence will be evaluated at 8-14 mo after completion of the 3-dose immunization course in study 105553 (NCT00307554). The immune response to a booster dose of GSK Biologicals' pneumococcal conjugate vaccine will also be evaluated when given at 12-18 mo to subjects not primed with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with GSK Biologicals' pneumococcal conjugate vaccine will receive a booster dose of the same vaccine. 2nd group of children primed with Prevenar™ will receive a booster dose of Prevenar™ (control group). 3rd group of children primed with Prevenar™ will receive a booster dose of GSK Biologicals' pneumococcal conjugate vaccine. All children will receive concomitantly a booster dose of DTPa-HBV-IPV/Hib vaccine.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a healthy male or female, 12 to 18 months of age at the time of vaccination, who received at least one dose of either pneumococcal conjugate vaccine or Prevenar™ during study 105553 and with written informed consent obtained from the parent/guardian of the subject.
Exclusion Criteria
- •use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the vaccination, or planned use during the entire study period (active phase and safety follow-up).
- •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before vaccination up to Visit
- •Administration of any additional pneumococcal vaccine or DTPa-combined vaccine since end of study
- •Children with a history of seizures or neurological disease, allergic disease, immunosuppressive or immunodeficient condition.
Outcomes
Primary Outcomes
Number of Subjects With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) Post Booster Between the Synflorix-Synflorix and Prevenar-Prevenar Groups
Time Frame: Within 4 days (Days 0-3) after the booster vaccination at Month 0 in this study 10PN-PD-DIT-007
Fever was measured as rectal temperature. Assessment of occurrences of rectal temperature \> 39.0 °C was performed post administration of the booster dose of pneumococcal vaccine (Synflorix™ or Prevenar™ vaccine) in this study. The analysis was performed on the Total vaccinated cohort, which included all subjects vaccinated in this study 10PN-PD-DIT-007, solely on subjects with results available.
Secondary Outcomes
- Number of Subjects Seroprotected as Regards Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antigens - by 22F-inhibition Enzyme-linked Immunosorbent Assay (ELISA)(Prior to (PRE) and one month after (Month 1) booster vaccination)
- Number of Subjects With Serious Adverse Events (SAEs) During the Active Phase of the Study(Throughout the Active Phase of the study, that is, within 31 days (Day 0-30) after the booster vaccination at Month 0 in this study 10PN-PD-DIT-007)
- Number of Subjects With Serious Adverse Events (SAEs) During the Entire Study(Throughout the study period, from Month 0 prior to booster vaccination up to Month 6, end of the ESFU in this study 10PN-PD-DIT-007)
- Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(Within 4 days (Days 0-3) after the booster vaccination at Month 0 in this study 10PN-PD-DIT-007)
- Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, 9V, -14, -18C, -19F and -23F) - by 22F-inhibition Enzyme-linked Immunosorbent Assay (ELISA)(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Number of Subjects Booster (BST) Responder to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin Antigens(One month (Month 1) post booster vaccination)
- Number of Subjects With Any and Any Grade 3 Solicited General Symptoms(Within 4 days (Days 0-3) after the booster vaccination at Month 0 in this study 10PN-PD-DIT-007)
- Number of Subjects With Unsolicited Adverse Events (AEs)(Within 31 days (Day 0-30) after the booster vaccination at Month 0 in this study 10PN-PD-DIT-007)
- Anti-diphtheria (Anti-D) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Antibody Concentrations to Protein D (Anti-PD) - by Enzyme-Linked Immunosorbent Assay (ELISA)(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Anti-pertussis Toxoid (Anti-PT), Anti- Filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations(Prior to (PRE) and one month (Month 1) post booster vaccination)
- Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations(Prior to (PRE) and one month (Month 1) post booster vaccination)